{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T22:25:25Z","timestamp":1761171925130,"version":"build-2065373602"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated substantial clinical activity in metastatic HER2-positive breast cancer. Although durable responses are increasingly reported, the potential for long-lasting remission after treatment discontinuation remains poorly documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases<\/jats:title>\n                    <jats:p>We report two patients with metastatic HER2-positive breast cancer who experienced exceptional and sustained clinical benefit with T-DXd. The first patient achieved a deep response lasting over 50 months, including 36 months of complete remission after treatment discontinuation due to thrombocytopenia. The second patient has maintained disease control for over 39 months, with a prolonged treatment pause. Both cases highlight remarkable disease stability beyond conventional expectations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These case reports highlight the potential of T-DXd not only to induce deep and durable responses but also to maintain disease remission beyond drug exposure in selected patients. Such observations challenge the paradigm of incurability in metastatic HER2-positive breast cancer and warrant further investigation into the mechanisms and predictors of long-lasting responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1647018","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:39Z","timestamp":1761106659000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exceptional responses to Trastuzumab deruxtecan in HER2-positive breast cancer: two illustrative case reports"],"prefix":"10.3389","volume":"15","author":[{"given":"Zelmira","family":"Ballatore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Vanacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Chiari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","unstructured":""},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01196-3","article-title":"Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer","volume":"24","author":"Shitara","year":"2021","journal-title":"Gastric Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102527","article-title":"Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review","volume":"115","author":"Bartsch","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102500","article-title":"The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer","volume":"113","author":"Von Arx","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2023.151554","article-title":"Current management and future perspectives in metastatic HER2-positive breast cancer","volume":"40","author":"Sanchez-Lorenzo","year":"2024","journal-title":"Semin Oncol Nurs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00971-9","article-title":"Trastuzumab deruxtecan: A review in unresectable or metastatic HER2-positive breast cancer","volume":"18","author":"Nie","year":"2023","journal-title":"Target Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104624","article-title":"Challenges and prospects in HER2-positive breast cancer-targeted therapy","volume":"207","author":"Li","year":"2025","journal-title":"Crit Rev Oncology\/Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086","article-title":"DESTINY-breast06 trial investigators. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3892\/ol.2023.14110","article-title":"Early thrombocytopenia predicts longer time-to-treatment discontinuation in trastuzumab emtansine treatment","volume":"26","author":"Sahin","year":"2023","journal-title":"Oncol Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124","article-title":"EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017","article-title":"KATHERINE Investigators. Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510","article-title":"DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Huang","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"DESTINY-Breast03 Trial Investigators. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110407","article-title":"T-DM1-induced thrombocytopenia in breast cancer patients: New perspectives","volume":"129","author":"Liu","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1048","article-title":"HER2-targeted immunoconjugates for breast cancer: Ancestry and dose adjustment for thrombocytopenia","volume":"40","author":"Rainone","year":"2023","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03383-x","article-title":"Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management","volume":"26","author":"Ciruelos","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06447-6","article-title":"Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis","volume":"191","author":"Honkanen","year":"2022","journal-title":"Breast Cancer Res Treat"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1647018\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:17:39Z","timestamp":1761106659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1647018\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1647018"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1647018","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1647018"}}